Zolmitriptan Nasal Spray
Formulated to address migraine headache and to alleviate associated nausea.
Strengths: 5mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Zomig
- Therapeutic class
Serotonin 5-HT1 Receptor Agonist
- Pharmacological class
Triptan
- Precautions and warnings
cardiac evaluation recommended before use; do not use for prophylaxis
- Minor side effects
dizziness; somnolence; paraesthesia
- Moderate side effects
nausea; dry mouth; muscle weakness
- Dosage forms
Nasal spray, solution
- Administration route
Nasal use
- Patient summary
Formulated to address migraine headache and to alleviate associated nausea.
- Prescription status
POM
- Manufacturer
AstraZeneca
- Onset Time
15–30 minutes
- Duration
4–6 hours
- Storage instructions
Store below 25°C, protect from light.
- Drug interactions
ergotamine; MAO inhibitors; SSRIs
- Age restrictions
Not for children.
Contraindications
history of myocardial infarction; uncontrolled hypertension; ischaemic heart disease
Serious side effects
myocardial ischaemia — requires immediate medical attention; coronary vasospasm — requires immediate medical attention
Mechanism of action
Zolmitriptan is a selective serotonin 5-HT1B/1D receptor agonist that constricts intracranial blood vessels and inhibits neurotransmitter release, effectively aborting migraine symptoms.
Pregnancy and breastfeeding
Pregnancy: Use only if benefit outweighs risk. Breastfeeding: Avoid during treatment.
Zolmitriptan Nasal Spray
Formulated to address migraine headache and to alleviate associated nausea.
Editorial Notes
- Active ingredient(s): Zolmitriptan
- Listed indication(s): Migraine
Available option
- 2 bottles - 5 mg1313-5-mg-15697